<DOC>
	<DOCNO>NCT01374308</DOCNO>
	<brief_summary>The general objective present clinical trial compare therapeutic efficacy combination therapeutic vaccine contain hepatitis B surface antigen ( HBsAg ) hepatitis B core antigen ( HBcAg ) [ later call NASVAC ] commonly use antiviral drug , pegylated interferon patient chronic hepatitis B ( CHB ) .</brief_summary>
	<brief_title>NASVAC Phase-III Trial Chronic Hepatitis B ( CHB ) Patients</brief_title>
	<detailed_description>To collect ass data therapeutic potential NASVAC CHB patient regard : Reduction serum HBV DNA level . Reduction level alanine aminotransferase ( ALT ) Clearance hepatitis B e antigen ( HBeAg ) Negativation lower HBsAg Anti-HBsAg/anti-HBeAg seroconversion An additional objective study reconfirm safety NASVAC CHB patient previously show u Phase I-II clinical trial CHB patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>HBsAg+ serology 6 month begin treatment . In last six month , accord HBeAg serostatus , : HBeAg ( ) patient , ) baseline HBV DNA ≥ 103 b ) raise serum ALT ( x &gt; 1 ULN ) significant hepatic necroinflammation and/or fibrosis ( HAINI &gt; 4 and/or HAIF &gt; 2 ) liver stiffness &gt; 7.2 KPa . HBeAg ( + ) patient , ) baseline HBV DNA ≥ 104 b ) raise serum ALT ( x &gt; 1.5 ULN ) significant hepatic necroinflammation fibrosis ( HAINI &gt; 4 and/or HAIF &gt; 2 ) liver stiffness &gt; 7.2 KPa . Patients sex 18 60 yearsold No specific hepatitis B treatment least 6 month previous inclusion Voluntary sign inform consent participate trial Condition HBV asymptomatic carrier cirrhosis patient primary hepatocellular carcinoma Positive serological marker hepatitis C Positive serological marker HIV Previous specific antihepatitis B treatment last 6 month . Critically ill patient history heart renal failure , hypertension , hyperthyroidism , epilepsy , immunodeficiency disease , malignancy noncontrolled systemic disease . Pregnancy nurse woman . Women fertile age without contraceptive method . Known severe allergic condition ( degree III IV asthma , urticaria , dermatitis , bronchitis , etc . hypersensitivity ingredient present preparation ) . Severe psychiatric dysfunction another limitation prevent patient 's consent . History Autoimmune disease ( SLE , rheumatoid arthritis , multiple sclerosis , non control diabetes mellitus type 1 ) History hepatic disease different etiology ( alcoholism , autoimmune hepatitis , drug induce hepatitis , Wilson 's disease , hemochromatosis ) History immune suppressive disorder administration immune suppressiveimmune modulator drug ( include steroid ) 6 month previous study . Very high transaminase level begin treatment ( ALT 500 U/L ) suggest stable disease risk patient 's health acute flare 15 time upper limit normality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>NASVAC</keyword>
	<keyword>Pegylated Interferon-2b</keyword>
	<keyword>CHB</keyword>
</DOC>